Advertisement
AdvertisementAdvertisement
logo

Anuh Pharma

ANUHPHR
Small Cap
(%) 1D
1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Anuh Pharma Share price and Fundamental Analysis

View All Details
View All Details
Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group.
Company Incorporation1960
ChairmanJasvantlal Shah
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
1,070.39
PE Ratio
22.6
Industry P/E
30.53
PEG Ratio
-1.07
ROE
14.52%
ROCE
18.29%
ROA
9.35%
Total Debt (Cr)
10.89
Debt to Equity
0.03
Dividend Yield
0.7%
EPS
9.45
Book Value & P/B
65.06 x 3.28
Face Value
5
Outstanding Shares(Cr)
5.01
Current Ratio
2.24
EV to Sales
1.6

Stock Returns

1 Week-2.1%
1 Month+25.3%
6 Months-4.23%
1 Year-4.23%
3 Years-4.23%
5 Years-4.23%

CAGR

1 Year CAGR

Revenue Growth

+22.66%

Net Profit Growth

+66%

Operating Profit Growth

+52.03%

Dividend Growth

+25%

Stock Returns CAGR

-4.23%
no_data

No Stocks

Smart Score

2.7
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

No data
Credit Rating
Director Report
Chairman Report
Auditor Report

Cashflow Statement

No data
Mar 25

Promoters : 69.92%

FIIs : 0.04%

DIIs : 0.00%

Public : 30.05%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 0.02% to 0.04% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

No data

Anuh Pharma Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

No data

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios
No data

Documents

Annual Reports
Con-Call

News

Anuh Pharma Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group.

Anuh Pharma Ltd was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs.

The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries.

During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg.

During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production.

In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption.

In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption.

In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.

Anuh Pharma Share Price

Anuh Pharma share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Anuh Pharma Market Cap

Market capitalization of Anuh Pharma indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Anuh Pharma is valued compared to its competitors.

Anuh Pharma PE Ratio

Anuh Pharma PE ratio helps investors understand what is the market value of each stock compared to Anuh Pharma 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Anuh Pharma PEG Ratio

The PEG ratio of Anuh Pharma evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Anuh Pharma ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Anuh Pharma generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Anuh Pharma ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Anuh Pharma in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Anuh Pharma Total Debt

Total debt of Anuh Pharma shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Anuh Pharma Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Anuh Pharma compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Anuh Pharma CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Anuh Pharma over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Anuh Pharma Technical Analysis

Technical analysis of Anuh Pharma helps investors get an insight into when they can enter or exit the stock. Key components of Anuh Pharma Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Anuh Pharma shares often struggle to rise above due to selling pressure.

Anuh Pharma Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Anuh Pharma ’s financial health and profitability.

Anuh Pharma Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Anuh Pharma Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Anuh Pharma Financials

The financials of Anuh Pharma provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Anuh Pharma Profit and Loss Statements

The profit and loss statement of Anuh Pharma highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Anuh Pharma .

Anuh Pharma Balance Sheet

The balance sheet presents a snapshot of Anuh Pharma ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Anuh Pharma Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App